SCHEMBL16618849

SCHEMBL16618849

COC(=O)c1cn(S(=O)(=O)c2cccnc2)c2cc(Br)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
HSD17B10 Q99714 1/20 0.47
NR4A2 P43354 4/20 0.45
AKR1C3 P42330 1/20 0.43
AKR1C1 Q04828 1/20 0.43
TSHR P16473 1/20 0.41
PLK1 P53350 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PRPS1 P60891 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PIK3CG P48736 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ALPL P05186 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19971360 0.88 AKR1C3 (0.56) KMT2AMEN1HSD17B10AKR1C3AKR1C1
SCHEMBL17422835 0.87 KMT2A (0.73) KMT2AMEN1NR4A2AKR1C3AKR1C1
SCHEMBL28207078 0.86 KMT2A (0.76) KMT2AMEN1NR4A2AKR1C3AKR1C1
SCHEMBL16618555 0.84 KMT2A (0.52) KMT2AMEN1NR4A2LMNASMN1; SMN2
SCHEMBL16618580 0.82 NR4A2 (0.50) KMT2AMEN1NR4A2TSHRPLK1
SCHEMBL16619065 0.82 NR4A2 (0.49) KMT2AMEN1NR4A2TSHRPIK3CG
SCHEMBL28068087 0.82 KMT2A (0.49) KMT2AMEN1NR4A2KDM4ELMNA
SCHEMBL19971364 0.81 HSD17B10 (0.39) HSD17B10AKR1C3AKR1C1TSHRPLK1
SCHEMBL16618966 0.79 KDM4E (0.45) KMT2AAKR1C3AKR1C1KDM4EHDAC1
SCHEMBL16618784 0.79 HTR6 (0.43) KMT2AAKR1C3AKR1C1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US claimed
EP-3052484-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2016-08-10 EP claimed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US claimed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO claimed
CN-105612150-B Sulfonylindole derivatives and process for producing the same 株式会社大熊制药 2018-04-10 CN disclosed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
EP-3052484-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2016-08-10 EP disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI KMT2A 3300/4885MEN1 1980/4885HSD17B10 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.